Robert J Matusik

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Dna Methylation

Angiotensin Converting Enzyme

Lower Urinary Tract Symptoms

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Renjie Jin, Connor M Forbes, Nicole L Miller, John T Lafin, Douglas W Strand, Thomas Case, Justin Merrill Marken Cates, Qi Liu, Marisol Ramirez-Solano, James L Mohler, Robert J Matusik
Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance. The Prostate 84 (5) (2024)
Renjie Jin, Connor M Forbes, Nicole L Miller, John T Lafin, Douglas W Strand, Thomas Case, Justin Merrill Marken Cates, Qi Liu, Marisol Ramirez-Solano, James L Mohler, Robert J Matusik
Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance. The Prostate 84 (5) (2024)
Renjie Jin, Connor M Forbes, Nicole L Miller, John T Lafin, Douglas W Strand, Thomas Case, Justin Merrill Marken Cates, Qi Liu, Marisol Ramirez-Solano, James L Mohler, Robert J Matusik
Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance. The Prostate (2024)
Renjie Jin, Connor M Forbes, Nicole L Miller, Douglas W Strand, Thomas Case, Justin Merrill Marken Cates, Hye-Young H Kim, Phillip A Wages, Ned A Porter, Krystin M Mantione, Sarah Burke, James L Mohler, Robert J Matusik
Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients. The Prostate 82 (14) (2022)
RenJie Jin, Douglas W Strand, Connor M Forbes, Thomas Case, Justin M M Cates, Qi Liu, Marisol Ramirez-Solano, Ginger L Milne, Stephanie Sanchez, Zunyi Y Wang, Dale E Bjorling, Nicole L Miller, Robert J Matusik
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms. The Prostate 81 (13) (2021)